Global Tasosartan Market Size By Type (Product Type I, Product Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Tasosartan Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.1 billion by 2031, expanding at a CAGR of 6.0% during the forecast period from 2023 to 2031. Tasosartan, an angiotensin II receptor antagonist (ARB), is primarily used in managing hypertension and cardiovascular disorders. Market growth is driven by the increasing prevalence of hypertension globally, a surge in geriatric populations, and the growing awareness of cardiovascular health.

Drivers:

1. Rising Incidence of Hypertension and Cardiovascular Disorders:

Hypertension remains one of the most prevalent chronic health conditions worldwide. With a growing aging population and lifestyle-related factors such as poor diet, physical inactivity, and stress, the need for effective antihypertensive treatments like Tasosartan continues to rise.

2. Increased Awareness of Preventive Healthcare:

Public health campaigns and governmental efforts are boosting awareness about the importance of early diagnosis and treatment of hypertension. This is contributing to increased prescription volumes for ARBs like Tasosartan.

3. Expansion of Generic Drug Manufacturing:

The market is witnessing a surge in generic versions of Tasosartan, especially in emerging economies, enhancing accessibility and affordability, thereby driving market growth.

Restraints:

1. Side Effects and Safety Concerns:

Although Tasosartan is effective, concerns about side effects such as hypotension, renal dysfunction, and fetal toxicity during pregnancy can limit its use, especially in certain patient demographics.

2. Competitive Pressure from Other ARBs:

The market faces stiff competition from more established angiotensin receptor blockers (e.g., Losartan, Valsartan), some of which have broader clinical validation and physician preference.

Opportunity:

1. Emerging Markets and Untapped Populations:

Emerging economies in Asia-Pacific, Latin America, and Africa are witnessing a rapid rise in hypertension cases. These regions present substantial opportunities for market players to expand access through pricing strategies and public health collaborations.

2. Advancements in Drug Delivery Mechanisms:

Innovations such as sustained-release formulations and combination therapies with diuretics or calcium channel blockers offer promising avenues to enhance Tasosartan’s efficacy and compliance.

Market by System Type Insights:

Based on system type, Monotherapy Tasosartan held the largest market share in 2023 due to its focused use in first-line hypertension treatment. However, Combination Therapy Formulations (Tasosartan with diuretics or calcium channel blockers) are anticipated to register the fastest growth through 2031, supported by their superior efficacy in patients with comorbidities.

Market by End-use Insights:

The Hospital Pharmacies segment accounted for the highest revenue share in 2023, attributed to the high patient footfall and reliance on physician-prescribed treatments. The Online Pharmacies segment is expected to grow significantly over the forecast period due to the increasing trend of telemedicine and e-prescriptions.

Market by Regional Insights:

North America led the Tasosartan market in 2023, driven by a high prevalence of hypertension, advanced healthcare infrastructure, and strong regulatory support for ARBs. Meanwhile, Asia-Pacific is projected to witness the highest CAGR through 2031 due to urbanization, increased health awareness, and expanding healthcare access.

Competitive Scenario:

Key players in the global Tasosartan market include:

Novartis AG

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Dr. Reddy’s Laboratories

Mylan N.V.

Aurobindo Pharma Ltd.

Lupin Limited

Cipla Inc.

Torrent Pharmaceuticals

Glenmark Pharmaceuticals

These companies are investing in R&D, forming distribution partnerships, and focusing on the production of cost-effective generics to strengthen their market positions.

Scope of Work – Global Tasosartan Market

Report Metric Details

Market Size (2023) USD 1.3 Billion

Projected Market Size (2031) USD 2.1 Billion

CAGR (2023-2031) 6.0%

Market Segments By System Type (Monotherapy, Combination Therapy), By End-use (Hospitals, Retail Pharmacies, Online Pharmacies), By Region

Growth Drivers Increasing hypertension cases, rising geriatric population, awareness of cardiovascular health

Opportunities Expansion in emerging markets, innovation in drug delivery systems

Key Market Developments:

2023: Teva Pharmaceuticals launched a new generic version of Tasosartan in the U.S., expanding access to affordable hypertension management.

2024: Dr. Reddy’s Laboratories entered a distribution partnership across Southeast Asia to introduce its cardiovascular drug portfolio including Tasosartan.

2025: Lupin Limited announced clinical trials for a combination therapy involving Tasosartan and a calcium channel blocker targeting multidrug-resistant hypertension.

FAQs:

1) What is the current market size of the Global Tasosartan Market?

The market size was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Tasosartan Market?

The major driver is the rising prevalence of hypertension and cardiovascular diseases worldwide.

3) Which is the largest region during the forecast period in the Global Tasosartan Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to witness the fastest growth through 2031.

4) Which segment accounted for